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Longitudinal Health Insurance Database during 2000-2008. VTE cases were iden-
tified based on the disease diagnosis coding and anticoagulant prescription or 
surgical thrombectomy procedure from the claims of inpatient or emergency 
care. Using risk set sampling, ten controls were selected for each case, matched 
on age (± 5 years), entry date (± 180 days), cancer diagnosis and major surgery 
procedure. Use of antipsychotics classified into typical antipsychotics (TAPs) and 
atypical antipsychotics (AAPs) was evaluated in the 365 days prior to an index 
date. Confounding was adjusted using a summary risk score for VTE during condi-
tional multiple logistic regressions. Results: A total of 1,616 VTE cases and 16,026 
controls were identified. Any use of TAPs was associated with a 1.26-fold (95% CI, 
1.06-1.50) increased VTE risk compared with nonuse. The risk varied depending 
on specific TAP-use scenarios, with the greatest risk being observed for parenteral 
administration (ORadj, 1.82; 95% CI, 1.14-2.91), followed by high-average-daily dose 
(> 5 mg of olanzapine-equivalent dose; ORadj, 1.75; 95% CI, 1.23-2.50), long-term 
use (> 30 days; ORadj, 1.59; 95% CI, 1.17-2.17), and current use of TAPs (ORadj, 1.54; 
95% CI, 1.15-2.07). Conversely, the insignificant association between AAP use and 
VTE risk was found and remained across the abovementioned drug-use condi-
tions. ConClusions: Use of TAPs but not AAPs is associated with an increased 
VTE risk. Health care professionals should be vigilant about VTE development in 
postmenopausal women receiving TAPs, especially for those receiving parenteral 
administration or high doses of TAPs.
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SimVaStatin and itS Potential drug interaCtionS: an analySiS of 
Safety Signal BaSed on fda aerS dataBaSe
Desai A.M., Cavanaugh T.M., Kelton C.M., Heaton P.C., Guo J.J.
University of Cincinnati, Cincinnati, OH, USA
objeCtives: Simvastatin is an antihyperlipidemic agent used to lower serum cho-
lesterol. Simvastatin has been associated with rhabdomyolysis, a rare but potentially 
life-threatening Adverse Drug Event (ADE). Recently, the FDA created a black box 
warning limiting use of simvastatin at higher doses. The objective of this study was 
to evaluate the data in the FDA Adverse Event Reporting System (FAERS) to describe 
and profile the cases that led to this decision. Methods: A retrospective analy-
sis of all domestic and foreign reports of simvastatin-associated rhabdomyolysis 
between October 1997 and September 2011 was conducted using FAERS database. 
The frequency of the following outcomes was examined: congenital anomaly, death, 
life-threatening reaction, hospitalization, disability, others and required interven-
tion. The percentage of role codes (primary suspect, secondary suspect, concomitant 
drug, or interacting drug) was analyzed. Separate analysis was conducted to report 
frequency of doses associated with rhabdomyolysis. Drug dosages associated with 
both ADEs and specifically rhabdomyolysis were evaluated. Results: A total of 
3,014,229 simvastatin-associated reports were identified over a 14-year period in 
the FAERS database. Hospitalization occurred in 41.1% and death was reported in 
8.16% of the cases. Remarkably, 40.4% of ADE were reported for the 40mg dose and 
13.4% for the 80mg dose. Simvastatin was designated as concomitant in 73.6% and 
as a secondary suspect in 16.0% of the cases. A total of 25,701 reports of simvastatin-
associated rhabdomyolysis were reported. Of these, 6,673 rhabdomyolysis reports 
had dose information avaialble. Whereas, 44.1% were associated with the 40 mg 
dose; 26.7% were reported for 80mg dose. ConClusions: Simvastatin-associated 
ADE were demonstrated in the FAERS database with severe clinical outcomes includ-
ing hospitalization and death. The increased risk associated with higher simvastatin 
doses provides evidence to support the FDA’s black box warning.
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infarCtion in PatientS With tyPe 2 diaBeteS
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objeCtives: Beta-blockers remain important for secondary prevention after 
myocardial infarction (MI). Despite recommendations in clinical guidelines, the 
potential for poor glycemic control and difficulties in identifying warning signs 
of hypoglycemia limit their utilization in patients with type 2 diabetes (T2DM). To 
date, limited research evaluated differences in safety and efficacy based on differ-
ences in pharmacologic properties of beta-blockers. This study evaluated factors 
predicting post-MI beta-blocker utilization among T2DM patients. Methods: A 
retrospective cohort of employed, commercially insured individuals with depend-
ents was developed using de-identified patient enrollment files, medical claims, 
and pharmacy claims from 2007-2009. Inclusion criteria: (1) T2DM, (2) ≥ 18 years 
old, (3) continuous eligibility, (4) MI. Exclusion criteria: (1) females prescribed 
metformin exclusively without T2DM diagnosis codes, (2) < 6 months eligibil-
ity pre-MI, (3) MI before first T2DM date, (4) beta-blocker use pre-MI, (5) lack of 
comorbidity data. Bivariate statistics compared new beta-blocker users to non-
users. Multivariate logistic regression with odds ratios (OR) and 95% confidence 
intervals (95%CI) with manual backwards elimination was used to evaluate demo-
graphic characteristics and comorbidities as predictors of post-MI beta-blocker 
exposure. Results: Beta-blockers were used in 104 (28.5%) of the cohort with 
68.3% and 30.8% of new users receiving cardioselective and alpha-blocking beta-
blockers, respectively. Congestive heart failure (CHF) without hypothyroidism [OR: 
0.42; 95%CI: 0.18-0.95], cardiac arrhythmia without renal failure [OR: 0.46; 95%CI: 
0.23-0.92], hypothyroidism without CHF [OR: 0.17; 95%CI: 0.05-0.57], and renal 
failure without cardiac arrhythmia [OR: 0.23; 95%CI: 0.07-0.71] were statistically 
significant predictors of beta-blocker utilization. ConClusions: Our study evalu-
ated post-MI beta-blocker use in T2DM patients. We showed that T2DM patients 
with CHF, arrhythmias, hypothyroidism, or renal failure were less likely to receive 
beta-blockers post-MI. Although the results might not apply to older populations, 
our results support the need for further investigation to determine whether more 
T2DM patients could benefit from beta-blocker treatment post-MI.
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CharaCterization of iSChemiC Stroke PatientS and SeCond Stroke 
rateS By riSk SCoreS
Hunter T.D.1, Quiroz M.E.2, Gunnarsson C.1, Mollenkopf S.A.2
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objeCtives: To better understand the ischemic stroke population with respect to 
atrial fibrillation (AF), oral anticoagulation (OAC) usage, and second stroke rates 
as a function of baseline CHADS2 and CHA2DS2-VASc risk scores. Methods: The 
population consists of all patients in the Truven Health MarketScan® Commercial 
and Medicare Supplemental Databases between 01/01/2008 and 12/31/2011 with 
an index ischemic stroke event and data available ±12 months around the index 
event. CHADS2 and CHA2DS2-VASc risk scores were derived from diagnosis codes, 
procedure codes, and prescription drug usage within 12 months prior to the index 
stroke. Results: A total of 174,318 patients (age 66.6±15.4 years, 54.4% female) 
were included. Among these, 11.9% had an AF diagnosis and/or antiarrhythmic drug 
usage within the 12 months prior to their index stroke. AF rates rose from 2.4% to 
39.9% as baseline CHADS2 scores increased and from 2.0% to 41.6% with increasing 
CHA2DS2-VASc scores. Only 9.6% of patients were on OAC in the year prior to their 
index stroke (3.7% to 27.4% by increasing CHADS2 score; 3.2% to 28.1% by increasing 
CHA2DS2-VASc score), and 48.9% of patients with AF were on OAC. Just 5.3% had new 
AF diagnosed within 12 months after their index stroke. The rate of second stroke 
in the year after the index stroke was 35.0% (29.5% to 39.2% and 29.2% to 39.3% by 
increasing CHADS2 and CHA2DS2-VASc scores, respectively). ConClusions: Over 
one-third of all surviving stroke patients experienced second strokes in the year 
following their first stroke. Given the low rate of newly diagnosed AF, this suggests 
that undiagnosed AF may be an important contributor to the high recurrent stroke 
rate. Further study is required to determine if more rigorous post-stroke arrhythmia 
monitoring can lead to increased AF detection and OAC utilization, thus resulting 
in a reduction in recurrent stroke.
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objeCtives: It is frequently stated that records for reimbursement purposes may 
show higher mortality rates than what actually occurs. Among other causes, it may 
occur out of intentional and unethical misuse of the register (e.g. by including only 
severe cases) or due to lack of knowledge on how to register the data. The aim of the 
study was to evaluate the accuracy of a public registry system concerning hospital 
mortality in coronary artery bypass surgery (CABS). Methods: The hospital cohort 
is composed by a retrospective cohort sample of all adults undergoing CABS on the 
State of Rio de Janeiro, Brazil, from January to December 2007. One Cohort obtained 
the data directly in the hospitals (in-hospital mortality) through chart review using 
a standardized electronic form. The other cohort (Registry cohort) included data 
obtained in the Brazilian Registry of hospital admissions systems (SIH / SUS). To cal-
culate the 30-day mortality, data were added through probabilistic linkage resorting 
to software RecLink 3. The rates comparisons were calculated using the Chi square 
test. Results: Were included in the registry cohort 18,080 patients submitted to 
CABS with 1,028 deaths and in the hospital cohort 231 patients with 26 deaths. The 
median age of the hospital cohort was 68.6 years old; 68.4% male, 63.2% were elective 
surgery. The hospital cohort showed higher mortality rate (11.3%) when compared 
with the registry cohort (6.22 %) with significant p value (< 0.05). ConClusions: 
The surgical mortality was high both in the registry and in the hospital cohort. 
Comparing the two forms of data collection, it shows that the mortality rate is even 
higher when collected directly from the hospitals. It can be explained by a selection 
bias of patients for inclusion in the registry. The use of secondary data for economic 
analysis may lead to an underestimation of the mortality rates in CABS.
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PatientS
Tunceli O.1, Quinlan S.1, Balu S.2, Deshpande G.1, Anzalone D.2, Cziraky M.J.1, Jacobson T.A.3
1HealthCore, Inc., Wilmington, DE, USA, 2AstraZeneca, Wilmington, DE, 3Emory University School 
of Medicine, Atlanta, GA
objeCtives: To compare effectiveness of initiation of different statins on LDL-C 
reduction among high cardiovascular-risk patients. Methods: Patients aged ≥ 18 
years and newly initiating statin therapy (rosuvastatin, atorvastatin, simvastatin, or 
pravastatin) were identified from the HealthCore Integrated Research Environment 
(HIRE) from 1/1/2007–2/28/2013. Patients were required to have ≥ 2 LDL-C values 
(one pre- and post statin initiation). Patients were classified as high risk (coronary 
heart disease [CHD] or CHD risk equivalent) based on NCEP ATP III guidelines and 
were propensity score matched on several baseline characteristics. Absolute change 
from baseline to most recent LDL-C values obtained in the follow-up period and 
proportion of patients attaining 50% reduction in LDL-C were compared between 
rosuvastatin versus the other statins grouped together and versus atorvastatin 
alone. Results: There were 625 matched high-risk patients in both the rosuvas-
tatin versus the overall group and 544 in both the rosuvastatin versus atorvastatin 
cohorts. Average follow-up was 259 (rosuvastatin) vs. 263 (overall) days and 264 
(rosuvastatin) vs. 239 (atorvastatin) days. Mean baseline LDL-C value was 130 mg/
dl (rosuvastatin) vs. 128 mg/dL (overall) and 131 mg/dl (rosuvastatin) vs. 126mg/dL 
(atorvastatin). Average daily dose was 10 mg for rosuvastatin, 26 mg for the overall 
group, and 21 mg for atorvastatin. Absolute reduction in LDL-C was higher for the 
rosuvastatin group compared to either the overall group (52 vs. 43 mg/dL; p< 0.0001) 
or the atorvastatin group (53 vs. 47 mg/dL; p= 0.0005). Proportion of patients attain-
ing 50% reduction in LDL-C was significantly higher for the rosuvastatin versus the 
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overall group (33% vs. 20%; p< 0.0001) and versus the atorvastatin group (34% vs. 
24%; p < 0.0001). ConClusions: Propensity score-matched analysis of high-risk 
patients initiating statins indicated that rosuvastatin was significantly more likely 
to reduce LDL-C compared with all other statins grouped together and compared 
with atorvastatin alone in this real world patient population.
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SyStematiC reVieW and netWork meta-analySiS of all agentS for 
Stroke PreVention in PatientS With atrial fiBrillation
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objeCtives: To compare the relative effectiveness and safety of all stroke preven-
tion agents in patients with atrial fibrillation (AF) through a systematic review and 
network meta-analyses. Methods: A search of MEDLINE, EMBASE, and CENTRAL 
was conducted (through December 2013) to identify Phase III randomized controlled 
trials of AF patients, comparing any two of the following agents: placebo, aspirin, 
aspirin and clopidogrel combination therapy (A+C), adjusted-dose warfarin (target 
INR 2.0-3.0), dabigatran (110 mg and 150 mg), rivaroxaban, apixaban, and edoxaban 
(high and low doses). We conducted fixed-effects Bayesian network meta-analyses 
to generate relative effectiveness estimates for the outcomes of interest (all stroke, 
ischemic stroke, myocardial infarction, overall mortality, major bleeding, intrac-
ranial hemorrhage, and fatal bleeding). For each outcome, agents were ranked 
according to their likelihood of being the best option. Results: We identified 12 
studies, comprising 81,771 patients. Compared to warfarin, dabigatran 150 mg (RR 
0.65, 95% CI 0.52-0.82) and apixaban (RR 0.80, 95% 0.66-0.96) reduced the risk of 
all strokes. Dabigatran 150 mg was also more effective than warfarin at reducing 
ischemic stroke risk (RR 0.77, 95% CI 0.59 – 0.99). All anticoagulants were more effec-
tive than A+C, aspirin and placebo at reducing the risk of ischemic and all strokes. 
All treatments were associated with a lower risk of major bleeding than warfarin, 
except for dabigatran 150 mg, rivaroxaban, A+C, and aspirin. Dabigatran 150 mg 
was most likely to be ranked best at reducing ischemic stroke risk, and low-dose 
edoxaban as best at reducing major bleeding risk. ConClusions: Anticoagulants 
effectively reduce the risk of ischemic and all strokes in AF patients, and are more 
effective than antiplatelets. Some novel anticoagulants are associated with lower 
stroke and/or major bleeding risk than warfarin. In addition to a drug’s safety and 
effectiveness, individual treatment should consider the patient’s underlying stroke 
and bleeding risk profile.
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ComParatiVe effiCaCy of neW oral antiCoagulantS for Stroke 
PreVention in atrial fiBrillation among PatientS With Prior Stroke 
or SyStemiC emBoliSm
Cope S.1, Keen A.2, Chen M.2, Bergrath E.2
1Mapi, Toronto, ON, Canada, 2Mapi, Boston, MA, USA
objeCtives: Patients with atrial fibrillation (AF) and a previous stroke or tran-
sient ischaemic attack (TIA) have a high risk of stroke and may have a different 
baseline risk than patients without previous stroke or TIA, which may act as a 
treatment effect modifier. Therefore, the comparative efficacy of new oral antico-
agulants (NOACs) in terms of stroke or systemic embolism (SE) was assessed for 
the subgroup of patients with a previous stroke or TIA. Methods: A Bayesian net-
work meta-analysis (NMA) was performed for patients with previous stroke or TIA 
from three pivotal randomized controlled trials: ARISTOTLE, RE-LY, and ROCKET-AF, 
which compared apixaban, dabigatran, and rivaroxaban to warfarin, respectively. 
Parametric survival functions were used to model the hazard ratios (HR) over time 
for the compared interventions, and the difference in the shape and scale param-
eters of these functions was synthesized and indirectly compared. Results were 
compared to an analysis of constant HRs as well as to previous NMAs for this sub-
group. Results: The time-varying HRs for the treatments versus warfarin suggest 
that each NOAC is at least as efficacious as warfarin with respect to stroke and SE. 
The HR for dabigatran 150mg was fairly constant over time (range: 0.80-0.68). The 
HR for dabigatran 110mg decreased slightly over time (range: 1.82-0.40), whereas 
the HRs increased slightly over time for rivaroxaban (range: 0.61-1.34) and apixaban 
(range: 0.62-0.94). ConClusions: Based on the NMA of stroke or SE among patients 
with AF and a prior stroke or TIA, dabigatran 150mg and apixaban are expected to be 
comparable to warfarin; dabigatran 110mg is expected to be comparable to warfarin 
for the first 16 months and more efficacious up until 30 months; rivaroxaban is 
expected to more efficacious than warfarin for the first 4 months, and comparable 
to warfarin thereafter.
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a netWork meta-analySiS eValuating the CumulatiVe hazard rate 
of Stroke or SyStemiC emBoliSm for neW oral antiCoagulantS in 
Stroke PreVention for atrial fiBrillation PatientS
Cope S.1, Keen A.2, Bergrath E.2, Chen M.2
1Mapi, Toronto, ON, Canada, 2Mapi, Boston, MA, USA
objeCtives: In order to indirectly compare new oral anticoagulants (NOACs) for 
patients with atrial fibrillation (AF), several network meta-analyses (NMAs) have 
compared the number of patients with stroke or systemic embolism (SE) at study 
end. The aim of the present analysis was to assess the comparative efficacy of 
NOACs over the entire duration of the studies, including changes in compara-
tive efficacy over time, using the published cumulative hazard rates. Methods: 
A Bayesian NMA was performed using a fractional polynomial model synthesiz-
ing data from three pivotal randomized controlled trials: ARISTOTLE, RE-LY, and 
ROCKET-AF, which evaluated apixaban, dabigatran, and rivaroxaban, respectively, 
versus warfarin. Parametric survival functions were used to model the hazard rate 
over time for the compared interventions and the difference in the shape and 
scale parameters of these functions was synthesized and indirectly compared. 
The efficacy of NOACs was evaluated and compared to constant HRs from previ-
ous NMAs. Results: The time-varying hazard ratios (HRs) versus warfarin suggest 
that each NOAC is at least as efficacious as warfarin with respect to stroke and SE. 
The HR for dabigatran 110mg was fairly constant over time (range: 0.92-0.90). The 
HR for dabigatran 150mg decreased slightly over time (range: 0.78-0.56), whereas 
the HRs increased slightly over time for rivaroxaban (range: 0.59-1.17) and apixaban 
(range: 0.55-1.11). The HRs for each treatment comparison versus warfarin were 
transformed into cumulative hazard rates per treatment. ConClusions: Based on 
the NMA of stroke or SE among the intention to treat population with AF, dabigatran 
110mg is expected to be comparable to warfarin; dabigatran 150mg is expected to 
be comparable to warfarin for the first 5 months and more efficacious up until 30 
months; rivaroxaban and apixaban are expected to more efficacious than warfarin 
for the first 11 and 12 months, respectively, and comparable to warfarin thereafter.
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attainment on CardioVaSCular outComeS in PatientS With aCute 
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objeCtives: Despite the known benefit of low-density lipoprotein cholesterol 
(LDL-C) goal attainment of less than 70 mg/dL in a reduced risk of cardiovascular 
events, its effectiveness in acute coronary syndrome patients in Thailand is limited. 
This study aimed to assess the effect of LDL-C goal attainment on first composite 
cardiovascular outcomes. Methods: A retrospective cohort study was conducted 
using medical charts of patients who were hospitalized for acute coronary syndrome 
and were treated with statins at a tertiary care hospital in Thailand between 2009 
and 2012. After admission, patients were followed from the date of LDL-C goal 
assessment until the first event of composite cardiovascular outcomes (myocardial 
infarction, stroke, death). Median follow-up time was 544 days (interquartile range: 
224-887 days). Cox proportional hazard models were used to determine the effect 
of LDL-C goal attainment on the cardiovascular outcomes. Results: A total of 405 
patients were included. Mean age was 65 years (60% males). Twenty-seven percent 
of the patients attained a LDL-C goal of < 70 mg/dL, 38% had LDL-C between 70 
and 99 mg/dL and 35 % had LDL-C ≥ 100 mg/dL. Forty-six patients experienced a 
composite cardiovascular outcome. Patients achieving a LDL-C of < 70 mg/dL was 
associated with a lower composite cardiovascular outcome compared to patients 
with a LDL-C ≥ 100 mg/dL (adjusted HR= 0.41; 95% CI= 0.18 – 0.93; p-value= 0.034). 
Patients with a LDL-C between 70-99 mg/dL had a lower composite cardiovascular 
outcome compared to patients with a LDL-C ≥ 100 mg/dL but was not statistically 
significant (adjusted HR= 0.72; 95%CI= 0.37 – 1.42; p-value= 0.346). ConClusions: 
Acute coronary syndrome patients who received statins and achieved a LDL-C of 
< 70 mg/dL were more likely to have less cardiovascular outcomes, confirming the 
data from clinical trials that “the lower LDL-C the better”. Improvements in goal 
attainment for LDL-C are encouraging.
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ComParatiVe effeCtiVeneSS and Safety of CryoCatheter aBlation 
VerSuS radiofrequnCy Catheter aBlation for taChyarrhythmiaS: a 
SyStematiC reVieW
Park D.A., Lee N.R., Park S.H., Shin S.
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objeCtives: Tachyarrhythmias is a significant burden to a variety of cardiovas-
cular conditions and increased rates of stroke, death. The aim of this study was 
to critically evaluate the current evidence on the use of cryocatheter ablation (CA) 
compared with radiofrequency catheter ablation (RFCA) in patients with tachyar-
rhythmias. Methods: We searched potentially relevant studies using electronic 
databases such as Ovid-Medline, Ovid-EMBASE, Cochrane library, and two local 
medical databases through April 2013. Two independent reviewers extracted data 
from each study using a standardized form. Disagreements between reviewers 
were resolved by discussion or in consultation with a third reviewer. The quality of 
the selected studies was assessed using the Cochrane risk of bias for randomized 
controlled trials (RCTs). A fixed-effects model was used to combine trials and the 
dichotomous data were presented as relative risk (RR) with 95% confidence intervals 
(CI). Results: A total of 9 RCTs representing 1,202 patients were included. Their 
methodological quality was mostly poor. In 3 trials of atrial flutter, cryoablation, 
in comparison with RFCA, did not result in statistically significant difference in 
freedom from atrial flutter (RR 0.97, 95% CI 0.90-1.05, P= 0.43, I2= 0%). The incidence 
of freedom from atrial fibrillation was 80% in the cryoablation group compared with 
63.3% in the RFA group; this difference was not significant (RR 1.26, 95% CI 0.91-1.75, 
P= 0.16). In paroxysmal supraventricular tachycardias (PSVT), cryoablation signifi-
cantly decreased freedom from AVNRT or clinical recurrence (RR 0.95, 95% CI 0.91-
0.98, P= 0.003, I2= 0%). Major complications were not reported in the trials and the 
incidence of complications did not reported significant different. ConClusions: 
There is limited evidence to confirm the relative advantages and disadvantages of 
cryoablation versus radiofrequency ablation in patients with tachyarrhythmias. 
Further rigorous RCTs with long-term follow up that overcome the many limitations 
of the current evidence are warranted.
PCV22
meta-analySiS of Safety of daBigatran and Warfarin for atrial 
fiBrillation
Aggarwal S., Kumar S., Segal J.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have shown 
safety and efficacy for treatment of AF. The objective of this study was to conduct 
meta-analysis and present evidence for safety of Dabigatran versus Warfarin for 
treatment of AF. Methods: For this meta-analysis we included randomized con-
